Iambic Therapeutics, Inc.
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and…
Company newsroom
NASDAQ:IAM
1 releases
Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and…